DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

AbbVie Inc. (NYSE: ABBV)

65.48 -0.17 (-0.26%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ABBV $65.48 -0.26%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $65.48
Previous Close $65.65
Daily Range $65.31 - $65.87
52-Week Range $51.37 - $70.76
Market Cap $104.3B
P/E Ratio 58.62
Dividend (Yield) $2.04 (3.1%)
Ex-Dividend Date
Dividend Pay Date
04/13/15
05/15/15
Volume 14,041,469
Average Daily Volume 10,505,521
Current FY EPS $4.23

Sector

Industry

AbbVie Inc. (ABBV) Description

AbbVie Inc. Website: http://www.abbvie.com/

News & Commentary Rss Feed

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

5 Investments That Show John Paulson Knows How to Play M&A

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacy

AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog

Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog

Scott Black's Most Heavily Weighted Trades In Q1 2015

Achillion Pharmaceuticals: Should You Buy After The Sell-Off?

What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?

Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update

Achillion and Johnson & Johnson in $1.1B HCV Tie-Up - Analyst Blog

Achillion and Johnson & Johnson in $1.1B HCV Tie-Up - Analyst Blog

See More ABBV News...